Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Advances in Cell Signaling Pathways: A Comprehensive Review

Journal of Cellular Biology·2024
Same author

Novel Approaches to Tissue Engineering and Regenerative Medicine

Nature Methods·2023
Same author

Understanding Molecular Mechanisms in Disease Progression

Cell Reports·2023
Same author

Genomic Profiling Reveals New Biomarkers for Early Diagnosis

Nature Genetics·2023
Same author

CRISPR-Based Screening Identifies Key Regulators of Cell Growth

Cell Reports·2022
Same author

Structural Insights into Membrane Protein Function

Journal of Cellular Biology·2022

相关实验视频

Updated: Jun 26, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

β-上腺素阻断剂在预防心脏突发死亡中的作用

B Pitt1

  • 1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0366.

Circulation
|January 1, 1992
PubMed
概括

贝塔上腺阻断剂在预防心脏突发死亡方面表现有前途,特别是在左心室喷射分数减少的患者中. 研究正在进行中,以探索它们的有效性,特别是新的血管扩展性质.

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 之前的抗心律失常药物试验 (心律失常抑制试验) 显示,在心脏病发作后的死亡率上,恩凯尼德和弗莱凯尼德的限制.
  • 低剂量的阿米奥达龙在患有低左心室喷射率的患者中预防突然心脏死亡方面也被证明是无效的.

研究的目的:

  • 审查β-上腺素阻断剂在预防心脏突发死亡方面的现有证据和机制.
  • 突出β-上腺素阻断剂的潜力,特别是在低左心室喷射率的患者中.
  • 为进一步研究引入新的具有血管扩展性质的测试β-上腺素阻断剂.

主要方法:

  • 对以前对β-上腺素阻断剂的研究进行审查.
  • 分析拟议的机制及其在预防心脏突发死亡方面的有效性.
  • 考虑具有血管扩展性质的新兴β-上腺素阻断剂.

主要成果:

  • 积累的证据表明,β-上腺素阻断剂在预防心脏突发死亡方面具有潜在的益处.
  • 对于低左心室喷射率的患者,特别有前途.
  • 具有血管扩展性质的新药提供了新的治疗途径.

结论:

  • 贝塔上腺阻断剂是预防心脏突发死亡的有希望的策略.

更多相关视频

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

相关实验视频

Last Updated: Jun 26, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

  • 需要进一步的研究,特别是在高风险人群中,比如那些左心室喷射率低的人群.
  • 新的β-上腺素阻断剂可能会提供更好的疗效和安全性.